Raymond Keith Cross Jr. MD MS, AGAF, FACG
Inflammatory Bowel Disease
Professor of Medicine Director, IBD Program Co-Director, Digestive Health Center
Join to View Full Profile
685 W. Baltimore Street, Suite 8-00Baltimore, MD 21201
Phone+1 410-706-6012
Fax+1 410-706-4330
Dr. Cross is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandFellowship, Gastroenterology, 2004- University of MarylandResidency, Internal Medicine, 1997 - 2001
University of Pittsburgh School of MedicineClass of 1997
Certifications & Licensure
MD State Medical License 2000 - 2026
PA State Medical License 2020 - 2022
American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
Clinical Trials
- The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis Start of enrollment: 2008 Jan 01
- The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis Start of enrollment: 2008 Oct 01
- Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Start of enrollment: 2012 Sep 01
Publications & Presentations
PubMed
- Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study.Laurent Peyrin-Biroulet, Raja Atreya, Silvio Danese, James O Lindsay, J Casey Chapman
Journal of Crohn's & Colitis. 2025-12-23 - 3 citationsThe intestinal mucosa-associated microbiota in IBD-associated arthritis displays lower relative abundance of.Madeline Alizadeh, Uni Wong, Bernadette C Siaton, Michael T France, Seema A Patil
Gut Microbes. 2025-12-01 - Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.Adam S Faye, David T Rubin, Corey A Siegel, Millie D Long, Nabeel Khan
Inflammatory Bowel Diseases. 2025-11-22
Journal Articles
- A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)David A Schwartz, Mahrukh Riaz, Raymond K Cross, Seema A Patil, Sandra M Quezada, Barathi Sivasailam, Sara N Horst, Miguel Regueiro, Leyla Ghazi, Nature
- Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s DiseaseSeema A Patil, Raymond K Cross, Digestive Diseases and Sciences
- Correction to: Inflammatory Bowel Diseases Can Adversely Impact Domains of Sexual Function Such as Satisfaction with Sex LifeMichael D Kappelman, Swathi Eluri, Robert S Sandler, Millie D Long, Raymond K Cross, Digestive Diseases and Sciences
Authored Content
- An Update on Safety of Janus Kinase Inhibitors in Treatment of Patients with IBDJune 2024
- Steroids: Never or ForeverDecember 2022
- A Dog Is a Child's Best FriendMay 2022
Press Mentions
Treat IBD with Confidence: Clinical Strategies That Make a DifferenceApril 30th, 2025- Raymond Cross, MD, on JAK Inhibitors in IBDApril 10th, 2025
- What Is Infusion for Ulcerative Colitis?March 24th, 2025
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
